A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
NCT ID: NCT01539395
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2012-01-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
NCT01541618
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853
DECISIve - DiagnosE Using the Central veIn SIgn v1.0
NCT05533905
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655
Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment
NCT05834335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inactive Disease
Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
MSDx Complex-1 Biomarker Test
A biomarker test for the level of MSDx Complex-1
Active Disease
Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
MSDx Complex-1 Biomarker Test
A biomarker test for the level of MSDx Complex-1
Active Disease - Steroid Therapy
Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
MSDx Complex-1 Biomarker Test
A biomarker test for the level of MSDx Complex-1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MSDx Complex-1 Biomarker Test
A biomarker test for the level of MSDx Complex-1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects must be in generally good health.
3. Subjects must be able and willing to comply with the requirements of the protocol.
4. Must be diagnosed with RRMS
5. Meets the criteria to enter Group 1 or Group 2
Exclusion Criteria
2. Subject currently has a condition such as active influenza that would stimulate the immune system
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MSDx, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeanette K Wendt, MD
Role: PRINCIPAL_INVESTIGATOR
Northwest NeuroSpecialists, PLLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSDX0211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.